Promising COVID-19 Immunotherapy Targets CCR5

Clinical OMICs
America/Los_Angeles (PT) -7


IncellDx specific companion diagnostic tests can determine the efficacy and dosing by using leronlimab (monoclonal antibody under flow cytometry) in severe cases of COVID-19 to determine the presence of CCR5. Evaluation of test results found that patients with severe COVID-19 disease are in the midst of immunologic chaos which includes the cytokine storm. IncellDx's companion diagnostics show that after three days of therapy, the immune profile in these patients approach normal levels and the levels of cytokines involved in the cytokine storm are much improved. Droplet Digital PCR (ddPCR) meets both testing needs for sensitivity and precision and has emerged as a go-to method for assessing the quality of patient-derived DNA samples from plasma. In this Clinical OMICs webinar, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for the treatment of COVID-19.

Promising COVID-19 Immunotherapy Targets CCR5


Previous registration necessary?


Simultaneous translation ?


Will it be recorded?


Bruce Patterson


Link to the Event

Banner to the Event

Promising COVID-19 Immunotherapy Targets CCR5

Download the Agenda

Search for our next event. See you soon!

Subscribe to get news on all upcoming events


Social Media

  • Twitter DocMeetings
  • Instagram DocMeetings
  • Facebook ícone social
  • LinkedIn ícone social

contact us


Sao Paulo, SP - Brazil

© 2020 by Docmeetings - A Company
Site Managed by:
QUALITY Soluções Web
1996-2021 "25 years inspiring technology"